Abstract: Compositions of highly complex oxides that exhibit low thermal inertia, which lead to decreased heat loss and increased engine efficiency, are provided for temperature swing coatings. The compositions include at least five constituent oxides greater than 5 mol %. The oxides may form single phase solid solutions or may form multiple phases. The oxide coating may be mixed with additional phases or have a high porosity to further decrease thermal inertia. The oxides may contain at least five of any of the following metals and/or semimetals: Sc, Y, Ti, Zr, Hf, V, Nb, Ta, Cr, Mo, W, Mn, Re, Fe, Ru, Co, Ni, Cu, Zn, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Yb, Lu, Be, Mg, Ca, Sr, Ba, Al, Ga, Sn, Sb, Tl, Pb, Bi, B, Si, Ge, As, Sb, Te, or Po.

Abstract: There are provided a sintered body having both excellent mechanical strength and translucency, a method for producing the same and an orthodontic bracket. A sintered body, comprising a crystal grain having a cubic domain and a tetragonal domain, a stabilizer and lanthanum being dissolved in zirconia to form a solid solution as a matrix, and the amount of stabilizer contained being 1% or more by mole and 6% or less by mole, in which an average torque strength is 1.00 kgf·cm or more, and an in-line transmittance is 35% or more for visible light having a wavelength of 600 nm at a sample thickness of 1 mm.

Abstract: A method for forming a refractory component of foundry system includes forming a preform from a refractory mixture. The refractory mixture includes a silicon carbide preceramic polymer and at least one of a refractory powder or refractory aggregate. The method further includes heating the preform to pyrolyze the silicon carbide preceramic polymer and form a refractory material defining the refractory component. The resulting refractory material includes at least one of the refractory powder or the refractory aggregate in a silicon carbide matrix. The refractory component defines an oxidation-resistant surface configured to contact molten metal.

Abstract: A method of forming a ceramic matrix composite includes arranging a plurality of ceramic fibers into a preform, mounting the preform within a tooling fixture, perforating the preform to form a plurality of z-channels, each of the plurality of z-channels extending completely through a thickness of the preform, pushing a pin array against a surface of the preform through infiltration holes in the tooling fixture to apply a compressive force on the preform, and subsequently, removing the pin array from the surface of the preform. The pin array includes a plurality of pins extending from a backplate. Each of the plurality of pins is aligned with a respective infiltration hole of the tooling fixture.

Abstract: The use of a grinding additive during the dry grinding of clay mineral, wherein the grinding additive is selected from the group consisting of alkanolamines, glycols, glycerol, sugars, sugar acids, carboxylic acids or their salts, superplasticizers, superabsorbent polymers, or mixtures thereof. Construction materials also include a ground clay mineral including the additives and the use of the ground clay mineral.

Abstract: A tooling fixture suitable for use in infiltrating a fibrous preform with a flow of reactant gas includes at least one wall. The at least one wall includes an outer surface and opposing inner surface defining a thickness therebetween, and a plurality of holes extending through the thickness. Each hole of the plurality of holes includes an inlet at the outer surface, an outlet at the inner surface, a transition point between the inlet and the outlet, and a first corner defined by the outer surface and the inlet. An angle of the first corner is less than 90 degrees, each hole of the plurality of holes has a first diameter at the inlet and a second diameter at the outlet, and the second diameter is less than the first diameter.

Abstract: A method is disclosed for the manufacture of a homogeneous, solid, particulate, urea-based composition comprising urea and an additive in a urea production plant comprising at least an evaporator section and a particulation section, further comprising one or more of a mixing section, an effluent gas treatment section and a scrubber solution storage section, comprising the steps of: (i) concentrating a urea melt of about 80 weight % to about 95 to 99 weight % of urea; (ii) particulating a urea or urea-based melt into a urea or urea-based composition; (iii) mixing the urea melt of about 95 to 99 weight % with other fertilizer components to produce a urea-based melt; (iv) treating the effluent gas from the particulation section comprising urea-based dust particles and ammonia gas with water to produce a scrubber solution; and (v) storing the scrubber solution from the effluent gas treatment section.

Abstract: Systems and processes for producing ammonia products and calcium carbonate products, the latter containing sequestered carbon dioxide, from an effluent derived from one or more organic feedstocks. Solids are removed from an organic feedstock that contains a nitrogen compound to produce an organic liquid effluent that contains ammonium and/or ammonia. Ammonia is stripped and concentrated from the organic liquid effluent to produce a gaseous mixture that contains ammonia and carbon dioxide, and the gaseous mixture is cooled to produce a condensed aqueous ammoniacal nitrogen solution of aqueous ammonia, ammonium bicarbonate, and/or ammonium carbonate. The condensed aqueous ammoniacal nitrogen solution is then contacted with a stabilizing agent to cause a reaction therebetween to produce at least a stabilized ammoniacal nitrogen product and calcium carbonate in which carbon dioxide captured in the ammonium bicarbonate and/or the ammonium carbonate is sequestered.

Abstract: The disclosure relates to a method for producing a soil amendment composition through a process involving the addition of ochre, phyllosilicate, and clay to water in a reactor, followed by agitation to form a clay slurry, and concluding with a drying phase to achieve a specified moisture content. This composition may improve soil fertility, stabilize organic matter, and support environmental sustainability efforts.

Abstract: The application includes a Brevundimonas and a use thereof in tea plant planting, belonging to the technical field of microorganisms. The Brevundimonas is Brevundimonas sp. AnNong-1 which is preserved in China Center for Type Culture Collection with a preservation number CCTCC M 20221537. The culture solution of the strain can significantly increase the function of the total amount of L-Theanine in first and second leaves of tea plants after being inoculated around a distance of about 5 cm from the roots of tea seedlings. The Brevundimonas sp. AnNong-1 of the present invention is easy to operate in fermentation conditions and can also be used for preparing a natural microbial fertilizer, which can significantly increase the content of L-Theanine without greatly affecting the content of tea polyphenol, thereby providing a choice for the tea market. The microbial fertilizer is an environmental-friendly fertilizer, and can greatly reduce environmental pollution.

Abstract: Methods for enhancing the growth and/or yield of plants, such as corn and wheat, through the application of one or more phosphate-solubilizing microorganisms and one or more lipo-chitooligosaccharides and/or chitooligosaccharides to plant seeds prior to planting.

Abstract: The present disclosure belongs to the field of microbial technology, and in particular relates to a microbial agent for promoting root nodule number increase and root nodule nitrogenase activity increase in leguminous crops and use thereof. The microbial agent is compounded from 4 microbes including Bacillus amyloliquefaciens, Brevibacillus laterosporu, Bacillus mucilaginosus Krassilnikov, and Enterobacter ludwigii by separate fermentative cultivation, concentration and mixing. The microbial agent can effectively promote root nodule number increase and root nodule nitrogenase activity increase, promote crop growth, and improve crop yield and product quality.

Abstract: The present invention relates to a gas/liquid reactor for the oligomerization of gaseous ethylene, comprising a central pipe which delimits inside the reactor chamber a central zone allowing a descending flow and an outer zone allowing an ascending flow, thus making it possible to increase the time of travel of the injected gas bubbles in the liquid phase, without increasing the volume of the liquid phase and thus the volume of the reactor.

Abstract: A method for producing olefins using a circulating fluidized bed process, includes: supplying a propane-containing hydrocarbon mixture and a dehydrogenation catalyst into a riser, which is a fast fluidization regime, to cause a dehydrogenation reaction; separating, from a propylene mixture, the catalyst which is a product of the dehydrogenation reaction; removing unseparated hydrocarbon compounds remaining in the catalyst separated in the separating; continuously regenerating the catalyst by mixing the catalyst stripped in the removing with a gas containing oxygen; circulating the catalyst regenerated in the continuously regenerating to the supplying and resupplying it into the riser; and preparing propylene by cooling, compressing, and separating the propylene mixture which is a reaction product separated in the separating.

Abstract: According to one or more embodiments, a method for forming light olefins may comprise introducing a hydrocarbon feed stream into a reactor, reacting the hydrocarbon feed stream with a dehydrogenation catalyst in the reactor to from a high temperature dehydrogenated product, separating at least a portion of the dehydrogenation catalyst from the high temperature dehydrogenated product in a primary separation device, combining the high temperature dehydrogenation product with a quench stream to cool the high temperature dehydrogenation product and form an intermediate temperature dehydrogenation product, and cooling the intermediate temperature dehydrogenation product to form a cooled dehydrogenation product.

Abstract: A process for the separation of a natural gas stream is provided. The process includes receiving an effluent gas flow from a first fractionator operating at a first pressure, splitting the effluent gas flow into a first stream and a second stream, and passing the first stream through a heat exchanger thereby causing a phase change of at least a portion of the first stream from a gaseous state to a liquid state. The process includes inserting the first stream into an upper portion of a second fractionator operating at a second pressure. The second pressure is lower than the first pressure. The process includes inserting the second stream into a lower portion of the second fractionator, and diverting liquids from a lower portion of the second fractionator to the first fractionator.

Abstract: Disclosed is method that involves subjecting a base material to an extraction process to extract hydrocarbon fractions having molecular weights within a desired range from the base material to generate a resultant extraction material comprising mostly if not entirely of hydrocarbon fractions having molecular weights within the desired range. In some embodiments, the extraction process can involve performing the extraction in iterations.

Abstract: The invention relates to a process for obtaining isobutene from an isobutene containing C4-hydrocarbon mixture (1) in a plant comprising an etherification unit (3), a first distillation unit (5), an ether cleavage unit (8) and a second distillation unit (10), the process comprising: (a) contacting the C4-hydrocarbon mixture (1) with a primary alcohol (2) and reacting the mixture with the primary alcohol in the presence of an acidic catalyst to form the corresponding alkyl tert-butyl ether as an intermediate product and diisobutene as a by-product in the etherification unit (3): (b) distilling the reaction mixture (4) from the etherification unit (3) in the first distillation unit (5), a C4-hydrocarbon raffinate being withdrawn as the overhead product (6), the alkyl tert-butyl ether and diisobutene being withdrawn as the liquid or vaporous bottom product (7), and vaporizing the bottom product (7) if it is withdrawn as a liquid: (c) reacting the vaporous bottom product (7) in the presence of an acidic catalyst

Abstract: Provided is a method for the production of refined, low-acetal ethanol, comprising providing a fermentation product produced by fermentation of a carbon source with an ethanol-producing organism, which fermentation product comprises between 30% wt and 99% wt ethanol, between 70% wt and 1% wt water and between 20 and 2000 parts per million acetal; contacting said fermentation product with an acid catalyst, whereby at least 20% of the acetal hydrolyses to form a hydrolysis product comprising ethanol, water, acetaldehyde and optionally residual acetal; and distilling said hydrolysis product, whereby distilled, low-acetal ethanol is formed.

Abstract: The present disclosure provides a method for co-producing a xylitol and a caramel pigment. The method includes: transporting a raw material of a xylose mother liquid in a raw material tank to a filter for filtering impurities to obtain a filtered raw material of the xylose mother liquid, and transporting the filtered raw material of the xylose mother liquid to a nanofiltration membrane device to obtain a decolorized xylose mother liquid; transporting the decolorized xylose mother liquid to a first ion exchange device to obtain an ion exchange liquid; and transporting the ion exchange liquid to a chromatographic separation device and obtaining an extracted liquid and a raffinate liquid; performing a refined hydrogenation process on the extracted liquid through a refined hydrogenation assembly to obtain a crystal xylitol, and performing a browning reaction process on the raffinate liquid through a browning reaction assembly to obtain the caramel pigment.

Abstract: Various embodiments disclosed relate to a method of preparing aryl fluorinated ether compounds. The method involves contacting an aryl halide with a fluorinated alcohol in the presence of a photocatalyst, a base, and irradiation with electromagnetic radiation comprising a wavelength between about 200 nm and about 800 nm. The present invention also provides a method of late-stage photochemical modification of a biologically active compound, such as drugs or agrochemicals. Fluorinated derivatives of griseofulvin, clofibrate, and 2,4-D methyl ester are described herein.

Abstract: The present invention relates to use of 2,3,6-Trimethyl-2-cyclohexen-1-one as aroma Ingredient. 2,3,6-Trimethyl-2-cyclohexen-1-one is used to impart an aroma impression which is reminiscent of animalic note, woody note, floral note, green note, minty note, dusty note, phenolic note, and/or camphoraceous note to a composition and also enhancing and/or modifying the aroma of a composition. The present invention is further directed to an aroma composition comprising 2,3,6-Trimethyl-2-cyclohexen-1-one and (i) at least one aroma chemical different from the 2,3,6-Trimethyl-2-cyclohexen-1-one or (ii) at least one non-aroma chemical carrier, or (iii) both (i) and (ii).

Abstract: A process for the formation of high-purity magnesium L-lactate crystals from homogenous and heterogenous decomposed organic waste is provided. The process provides magnesium L-lactate crystals with improved enantiomeric purity and overall purity which are particularly suitable for reuse in the production of new polylactic acid.

Abstract: A composition of lithium L-threonate and a pharmaceutical composition of an effective amount of lithium L-threonate and pharmaceutically acceptable excipients. A method of making lithium L-threonate, by reacting calcium L-threonate with Li2SO4 and Ba(OH)2, and producing lithium L-threonate. A method of making lithium L-threonate, by reacting calcium L-threonate with Li2SO4, and producing lithium L-threonate. A method making lithium L-threonate, by synthesizing L-threonic acid, reacting the L-threonic acid with Li2SO4, and producing lithium L-threonate. A method of treating bipolar disorder, by administering an effective amount of lithium L-threonate to a patient, and treating bipolar disorder. A method of treating a disease or disorder, by administering an effective amount of lithium L-threonate to a patient, and treating the disease.

Abstract: Provided are crystals comprising trans sodium crocetinate, compositions comprising the same, and methods of making and using such crystals.

Abstract: Novel Dithiane derivative and methyl cinnamate compounds are provided which exhibit activity for the treatment of immunological diseases, inflammation, obesity, hyperlipidemia, hypertension, neurological diseases, and diabetes.

Abstract: Impurities such as sulfur dioxide (SO2) are removed from trifluoroacetyl chloride (TFAC) through distillation, adsorption, or a combination thereof, and/or including the formation of an azeotrope or azeotrope-like composition including effective amounts of sulfur dioxide (SO2) and trifluoroacetyl chloride (TFAC). The trifluoroacetyl chloride (TFAC) thus purified may then be used in the manufacture of trifluoroiodomethane (CF3I). Also disclosed are azeotropes and azeotrope like compositions of sulfur dioxide (SO2) and trifluoroacetyl chloride (TFAC).

Abstract: Provided herein are compounds of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof described herein. Also provided herein are pharmaceutical compositions comprising a compound Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.

Abstract: Provided herein are arylcyclohexylamines and their use in the treatment of psychiatric disorders.

Abstract: The present invention is directed towards a process for the synthesis of compounds with the general formula (II) or their respective alkali metal salts by oxidation of compounds of general formula (I) with oxygen in the presence of a heterogeneous catalyst containing a metal of group 10 of the periodic table of the elements, wherein R1 and R2 and R3 are same or different and selected from H and C1-C6-alkyl, non-substituted or substituted with one or more moieties selected from COOH and O-R4 with R4 being selected from H and C1-C4-alkyl.

Abstract: A method of conversion of thioimidates into amidines includes reacting a starting material compound including a thioimidate with a nitrogen-containing reagent to form a product compound including an amidine in place of the thioimidate in the starting material compound. The nitrogen-containing reagent includes a primary amine, a secondary amine, an ammonium salt, or a combination thereof. The thioimidate includes —S—R1, wherein R1 is substituted or unsubstituted (C1-C20)hydrocarbyl. A method of forming a cyclized product includes intramolecularly reacting an amidine with a carbonyl carbon to form the cyclized product including a 4H-imidazolone and/or a derivative thereof.

Abstract: This invention relates to materials and methods for iodine capture from a variety of sources and media, and at water/organic solvent interfaces.

Abstract: Novel organoselenium selective ligands are presented and designed to determine metal ions in a sample. These ligands are used as complexing agents in a dispersive liquid-liquid microextraction procedure of copper and zinc ions. The procedure has a shortened extraction time, minimal organic solvent types, and lower amounts of solvents, as well as easy operation and high enrichment efficiency.

Abstract: A composition including ionizable lipids is provided. Also provided is a composition forming lipid nanoparticle, wherein the composition includes the ionizable lipid, a helper lipid, a sterol, and a PEGylated lipid conjugate. Also provided are methods of making the ionizable lipids. The ionizable lipids can include 2AEOAP2, 2AEOAP4, 2AELAP2, 2AELAP4, Lipid 16A, Lipid 16B, Lipid 16C, Lipid 16B, and Lipid 20B.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: The invention discloses small molecular compounds targeting SRSF6 protein, its preparation method and applications. The compound is shown in formula (I). This molecule can selectively inhibit abnormal cells with high expression of SRSF6, thereby reducing the occurrence of abnormal alternative splicing events and inhibiting the occurrence and development of tumors, especially colorectal tumors. It can be used as a candidate new drug for anti-colorectal cancer.

Abstract: Prodrugs of pharmacologically active 1,2,4-triaminobenzene derivatives of the General Formula (I); or pharmaceutically acceptable salts thereof, where the symbols R1, R2, R3, R4, R5 and R6a, R6b, and R6c and where the symbol Z are defined. Methods for the synthesis, purification, testing and use as prodrugs of pharmacologically-active agents at Kv7 ion channels are provided.

Abstract: The disclosure is in part directed to crystalline forms of 5-(3,4-dichlorophenyl)-N-((1R,2R)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide and pharmaceutical compositions thereof.

Abstract: Described herein are heterocyclic azide-containing monomer units, copolymers comprising such heterocyclic azide-containing monomer units, substrate-bound copolymers, and oligonucleotide-bound copolymers, methods for making such copolymers and reacting them with a substrate and/or oligonucleotide, and methods of using such copolymers for immobilization of oligonucleotides to a substrate, for example for use in DNA sequencing or other diagnostic applications.

Abstract: The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.

Abstract: The present invention relates to fused piperidinyl bicyclic, meta-substituted piperidinyl and their related compounds that modulate activities of mammalian C5a receptor by directly binding to the C5a receptor. The invention also relates to pharmaceutical compositions containing such compounds and their use in the treatment of a disease or a disorder involving pathogenic activation of C5a receptors.

Abstract: The present invention relates to novel crystalline forms of a quinolone compound of Formula (I). The invention also relates to processes for the preparation crystalline forms of the compound of Formula (I). Further the disclosure provides a process for the preparation of compound of Formula (I), intermediates, impurities and pharmaceutical compositions thereof.

Abstract: The invention relates in a first aspect to an azadibenzocyclooctyne derivative according to formula (I) or a salt thereof having specific substituents at the benzo rings of the DIBAC structure and having specific substituents connected to the nitrogen atom of the DIBAC structure. A second aspect of the invention is directed to a conjugate of formula (II), wherein a substituent R6 is connected to the N atom of the 8 membered ring of the DIBAC structure via a linker structure —C(?O)-[L]n-Z—. A third aspect of the invention relates to a method for the modification of a target molecule, wherein a conjugate according to the second aspect is reacted with a target molecule comprising a 1,3-dipole group or a 1,3-(hetero)diene group. In a fourth aspect, the invention is directed to the use of the conjugate according to the second aspect for bioorthogonal labeling and/or modification of a target molecule.

Abstract: Described herein are novel methods of synthesizing 5-Bromo-2-(3-chloro-pyridin-2-yl)-2H-pyrazole-3-carboxylic acid from pyrazole or pyrazole derivatives.

Abstract: The present invention relates to a series of novel benzoimidazole derivatives and their use.

Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.

Abstract: The invention provides compounds of formula (I), stereoisomers, and pharmaceutically acceptable salts thereof for use in the treatment or prevention of hypertension: wherein: R1 and R2 are independently selected from H, halogen, C1-6 alkyl, C1-6 haloalkyl, and —CN, provided that at least one of R1 and R2 is other than H; and R3 is a group of the formula: wherein: n is 0 or 1; R4 is H or C1-3 alkyl; L1 is a linking group selected from a bond, —(CH2)P— in which p is an integer from 1 to 3, and C3-6 cycloalkylene; and X is selected from: (i) an aryl group optionally substituted by one or more substituents selected from C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, halogen, and —CN; (ii) a 5 or 6-membered heterocyclic ring optionally substituted by one or more substituents selected from C1-3 alkyl, C1-3 alkoxy, C1-3haloalkyl, halogen, and optionally substituted phenyl; and (iii) a cycloalkyl group optionally substituted by one or more substituents selected from C1-3 alkyl, C1-3 haloalkyl, and halogen.

Abstract: Disclosed are novel heterocyclic compounds such as novel quinazoline compounds and pharmaceutical compositions thereof which may be used to treat or prevent malaria, HIV infection and cancer.

Abstract: Formation of methanoic acid, during the production of Hexahydro-1,3,5-trinitro-1,3,5-triazine and Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine via the legacy Bachmann nitrolysis process, is avoided when the workup is performed under neutralized, anhydrous conditions. The recovered anhydrous spent acid is used directly in successive nitrolysis batches with minimal processing. The yield and quality of the hexahydro-1,3,5-trinitro-1,3,5-triazine and octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine thus produced is equal to the yield and quality of the legacy process hexahydro-1,3,5-trinitro-1,3,5-triazine and octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine employing aqueous workup conditions.

Abstract: Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q1, Q2, Z, R, R1, R2, R3, R4 and R5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.